1.中华医学会肾脏病学分会肾性贫血诊断和治疗共识 专家组.肾性贫血诊断与治疗中国专家共识（2018 修 订版）[J].中华肾脏病杂志,2018,34(11):860-866.
2.Portolés J, Gorriz JL, Rubio E, et al. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease[J]. BMC nephrol, 2013,14(1): 2.
3.Sato Y, Fujimoto S, Konta T, et al. Anemia as a risk factor for all- cause mortality: Obscure synergic effect of chronic kidney disease[J]. Clin Exp Nephrol,2018, 22(2): 388-394.
4.Eriksson D, Goldsmith D, Teitsson S, et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia[J]. BMC Nephrol, 2016,17(1):97.
5.Hoshino J, Muenz D, Zee J, et al. Associations of hemoglobin levels with health-related quality of life, physical activity, and clinical outcomes in persons with stage 3-5 nondialysis CKD[J]. J Ren Nutr, 2020, 30(5):404-414.
6.Levin A，Thompson CR，Ethier J，et al.Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin[J]. Am J Kidney Dis,1999,34(1):125-134.
7.St Peter WL，Guo H，Kabadi S，et al.Prevalence，treatment patterns，and healthcare resource utilization in Medicare and commercially insured non- dialysis- dependent chronic kidney disease patients with and without anemia in the United States[J]. BMC Nephrol,2018,19(1):67.
8.Hayashi T,Joki N,Tanaka Y,et al.Anaemia and early phase cardiovascular events on haemodialysis[J]. Nephrology, 2016, 20:1-6.
9.Yogasundaram H,Chappell M,Braam B,et al.Cardiorenal Syndrome and Heart Failure - Challenges and Opportunities[J]. Can J Cardiol,2019,35(9):1208-1219.
10.Eusta Ce J A,Astor B,Muntner P M,et al.Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease[J]. Kidney International, 2004, 65( 3):1031-1040.
11.丁瑜, 王健, 梁新,等. 尿毒症毒素对甲酚对单核细胞体外释放炎症因子的影响[J]. 解放军医学杂志, 2015, 40(1):35-39.
12.LIU C,LI H.Correlation of the severity of chronic kidney disease with serumin flammation, osteoporosis and vitamin D deficiency[J]. Exp Therap Med,2019,17(1):368-372.
13.窦涪琳, 王杨威, 崔文鹏, 等 .微炎症状态与肾性贫血[J].中国血液净化, 2016, 15(3): 145-148.
14.肾性贫血诊断和治疗共识中国专家组. 肾性贫血诊断与治疗中国专家共识[J]. 中华肾脏病杂志, 2013, 29(5):389-392.
15.孙义, 蒋先洪. 尿毒症患者肠道菌群失调与微炎症状态的关系[J]. 中国医学前沿杂志：电子版, 2015,7(5):96-99.
16.Khalil SKM,Amer HA,El Behairy AM,et al.Oxidative stress during erythropoietin hyporesponsiveness anemia at end stage renal disease：molecular and biochemical studies[J].J Adv Res,2016,7(3):348.
17.肖佳,刘书馨,张爽.罗沙司他对促红细胞生成素抵抗的维持性血液透析患者炎症因子的影响[J]. 中国实用内科杂志, 2021, 41(12):1061-1063.
18. Garlo K , Williams D , Ma L , et al. Severity of Anemia Predicts Hospital Length of Stay But Not Readmission in Patients with Chronic Kidney Disease: A Retrospective Cohort Study[J].Medicine,2015,94(25)
19. Cotter J, Baldaia C, Ferreira M, et al. Diagnosis and treatment of iron-deficiency anemia in gastrointestinal bleeding: A systematic review[J]. World Journal of Gastroenterology,2020,26(45):7242-7257.
20. Lene,Russell,Lars, et al. Effects of anemia and blood transfusion on clot formation and platelet function in patients with septic shock: a substudy of the randomized TRISS trial.[J]. Transfusion, 2018,58(12).
21. Donadee C,Raat N,Kanias T,et al.Nitric Oxide Scavenging by Red Blood Cell Microparticles and Cell-Free Hemoglobin as a Mechanism for the Red Cell Storage Lesion[J]. Bmc Pharmacology, 2011, 11(1):1-1.
22. Daimon S,Terai H.Influence of Antiplatelet Medications on Bleeding Events in Hemodialysis Patients[J]. Therapeutic Apheresis & Dialysis, 2011, 15(5):454-459.
23. 中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20):1463-1502.
24. Vinhas J, Barreto C, Assun??o J, et al. Treatment of anaemia with erythropoiesis-stimulating agents in patients with chronic kidney disease does not lower mortality and may increase cardiovascular risk: a meta-analysis[J]. Nephron Clin Pract, 2012, 121(3-4):c95-c101.
25. Collister D, Komenda P, Hiebert B, et al. The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis[J]. Ann Intern Med,2016, 164(7):472-478.
26. Kershenovich S,Modiano M,Ewy GA.Markedly decreased coronary blood flow in secondary polycythemia[J]. Am Heart J,1992,123(2):521-523.
27. Sinha SD, Bandi VK, Bheemareddy BR, et al. Efficacy,tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized,phase-Ⅲ trial[J]. BMC Nephrol, 2019, 20(1): 90.
28. Bailie GR,Larkina M,Goodkin DA,et al.Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality[J].Kidney Int,2015,87(1):162-168.
29. Ribeiro S,Belo L,Reis F, et al. Iron therapy in chronic kidney disease: Recent changes, benefits and risks[J].Blood Rev, 2016, 30(1): 65-72.
30. Fishbane S, EL-Shahawy MA, Pecoits-Filho R, et al.Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study[J]. J Am Soc Nephrol, 2021, 32(3): 737-755.
31. Zhang X,Zhang Y,Wang P,et al.Adipocyte hypoxia-inducible factor 2α suppresses atherosclerosis by promoting adipose ceramide catabolism[J]. Cell Metab，2019，30（5）:937-951.
